07:00 , May 21, 2001 |  BC Week In Review  |  Clinical News

RegeneRx preclinical data

RGRX (formerly Alpha 1 Biomedicals Inc. ) published in Experimental Eye Research that TB4 accelerated corneal re-epithelialization following debridement compared to controls (p<0.01) in an animal model. RegeneRx Biopharmaceuticals Inc. (RGRX), Bethesda, Md.   Product:...
08:00 , Dec 22, 1997 |  BioCentury  |  Finance

Limping

With the BioCentury 100 Price Level Index falling another 2 percent last week (it's down nearly 22 percent since early October), three IPOs fell victim to the soft market....
08:00 , Dec 22, 1997 |  BC Week In Review  |  Company News

Alpha 1 Biomedicals, SciClone deal

SCLN acquired worldwide rights to ALBM's Zadaxin immunomodulator, which it previously had licensed from ALBM. SCLN will no longer pay royalties to ALBM. SCLN paid $1.93 million, consisting of $130,000 in cash and $1.8 million...
07:00 , Sep 15, 1997 |  BC Week In Review  |  Clinical News

SciClone regulatory update

European Patent No. 603,305 issued to the U.S. Army, Alpha 1 Biomedicals Inc. (ALBM, Bethesda, Md.) and Wayne State University (Detroit, Mich.). It covers use of thymosin alpha 1 to treat hepatitis C as a...
08:00 , Feb 12, 1996 |  BC Week In Review  |  Company News

Alpha 1 Biomedicals deal

ALBM terminated its agreement to merge with Alpha 1 Acquisition Corp. (formerly Microbio Inc., a Castle Group company. See BioCentury Sept. 18) after determining that the company may be required to license a U.S. patent...
08:00 , Dec 4, 1995 |  BC Week In Review  |  Company News

Alpha 1 Acquisition Corp., Alpha 1 Biomedicals deal

ALBM signed a definitive agreement to merge with Alpha 1 Acquisition Corp. , a company formed by the Castle Group of New York (Alpha 1 Acquisition originally was called MicroBio Inc., see BioCentury Sept. 18)....
08:00 , Nov 6, 1995 |  BC Week In Review  |  Company News

Alpha 1 Biomedicals, Cel-Sci deal

CELI (Alexandria, Va.) finalized its acquisition of ALBM's 50 percent interest in their joint venture, Viral Technologies Inc., by issuing 159,170 CELI common shares (see BioCentury Sept. 25). CELI, which closed at $4.50 on Friday,...
07:00 , Oct 2, 1995 |  BC Week In Review  |  Company News

Alpha 1 Biomedicals infectious diseases news

ALBM settled a securities class action suit that was filed against the company in the U.S. District Court for the District of Maryland in connection with the company's Thymosin alpha 1 antiviral product. The plaintiffs...
07:00 , Sep 25, 1995 |  BC Week In Review  |  Company News

Alpha 1 Biomedicals, Cel-Sci deal

CELI will purchase ALBM's 50 percent stake in Viral Technologies Inc., a 50/50 joint venture formed in 1986 to develop the HGP-30 peptide to treat AIDS, for 159,170 shares of CELI stock. CELI (Alexandria, Va.),...
07:00 , Sep 18, 1995 |  BC Week In Review  |  Company News

Alpha 1 Biomedicals, MicroBio Inc. deal

ALBM (Bethesda, Md.) entered into a letter of intent to merge into MicroBio, a company recently formed by The Castle Group of New York. The agreement is contingent upon MicroBio raising $5-$10 million and an...